Abivax Cash Flow Statement (2021-2025) | ABVX

Cash Flow Statement Dec2021 Dec2022 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Operating Activities
Net Income -66.11M-137.07M-46.57M-41.75M-60.65M-42.08M-55.09M-54.80M-179.28M
Depreciation and Depletion 0.16M0.27M0.20M0.20M0.19M0.24M
Share-based Compensation 6.25M-6.00M-10.89M4.76M4.93M-7.09M-18.73M
Deferred Taxes 0.06M
Gains from Investment Securities -0.42M-0.69M1.25M-0.29M1.14M-0.61M-34.54M
Asset Writedowns and Impairment -13.88
Change in Working Capital 1.42M1.43M0.01M-4.64M0.59M2.31M1.94M
Change in Receivables -0.74M5.06M-2.92M3.45M-2.27M5.03M-5.36M
Change in Account Payables 5.65M-24.21M15.01M0.18M13.42M1.11M-32.73M
Cash from Operations -37.76M-54.30M-38.86M-35.81M-35.00M-37.74M-83.33M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF) 0.23M0.39M0.27M0.30M0.29M0.28M0.32M
Investing Activities
Cash from Investing Activities 2.07M12.45M1.92M0.59M1.14M0.21M3.83M
Financing Activities
Other financing activities -0.00M0.00M0.02M-0.03M0.13M0.26M0.14M1.64M
Debt Issuance and Repayment
Long-Term Debt Issuances 26.75M25.76M-0.66M
Short-Term Debt repayments -0.16M-0.14M-0.14M-0.24M-0.26M-0.38M
Change in Capital Stock
Shares Issued 599.51M586.11M1,352.35M1,396.67M
Net Equity Issued and Repurchased 3.39M
Misc.
Cash from Financing Activities 23.03M20.59M-6.91M-6.23M-8.24M-9.92M705.48M
Exchange Rate Effect 1.43M0.49M-2.13M2.73M-0.74M-1.23M-8.36M
Beginning Cash Balance 69.44M27.50M271.07M262.47M239.41M198.17M154.11M108.95M68.99M689.40M
Free Cash Flow -37.76M-54.30M-38.86M-35.81M-35.00M-37.74M-83.33M
Net Cash Flow -12.66M-21.26M-43.85M-41.44M-42.11M-47.45M625.98M